Lung cancer cells survive epidermal growth factor receptor tyrosine kinase inhibitor exposure through upregulation of cholesterol synthesis

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) provide clinical benefits over chemotherapy for lung cancer patients with EGFR activating mutations. Despite initial clinical responses, long‐term efficacy is not possible because of acquired resistance to these therapies. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Howell, Mark C., Green, Ryan, Khalil, Roukiah, Foran, Elspeth, Quarni, Waise, Nair, Rajesh, Stevens, Stanley, Grinchuk, Aleksandr, Hanna, Andrew, Mohapatra, Shyam, Mohapatra, Subhra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003654/
https://www.ncbi.nlm.nih.gov/pubmed/32123859
http://dx.doi.org/10.1096/fba.2019-00081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003654/
https://www.ncbi.nlm.nih.gov/pubmed/32123859
http://dx.doi.org/10.1096/fba.2019-00081

Ejemplares similares